BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reed CC, Wolf WA, Cotton CC, Rusin S, Perjar I, Hollyfield J, Woosley JT, Shaheen NJ, Dellon ES. Optimal Histologic Cutpoints for Treatment Response in Patients With Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study. Clin Gastroenterol Hepatol. 2018;16:226-233.e2. [PMID: 28987502 DOI: 10.1016/j.cgh.2017.09.046] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 12.6] [Reference Citation Analysis]
Number Citing Articles
1 Xue Z, Miller TL, Abramson L, Thakkar KP, Ketchem CJ, Reddy S, Greenberg SB, Abichandani S, Chang NC, Eluri S, Reed CC, Dellon ES. Association of eosinophilic esophagitis with autoimmune and connective tissue disorders, and the impact on treatment response. Dis Esophagus 2022:doac043. [PMID: 35829628 DOI: 10.1093/dote/doac043] [Reference Citation Analysis]
2 Ocampo AA, Dellon ES. Worsened Fibrostenotic Outcomes in Eosinophilic Esophagitis Patients Due to COVID-19-Related Endoscopy Cancellations. Dig Dis Sci 2022. [PMID: 35790699 DOI: 10.1007/s10620-022-07610-9] [Reference Citation Analysis]
3 Lucendo AJ, Molina-Infante J. Current treatment options and long-term outcomes in patients with eosinophilic esophagitis. Expert Rev Clin Immunol 2022;:1-14. [PMID: 35770955 DOI: 10.1080/1744666X.2022.2096591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Facchin S, Calgaro M, Pandolfo M, Caldart F, Ghisa M, Greco E, Sattin E, Valle G, Dellon E, Vitulo N, Savarino EV. Salivary microbiota composition may discriminate between patients with eosinophilic oesophagitis (EoE) and non-EoE subjects. Aliment Pharmacol Ther 2022. [PMID: 35715947 DOI: 10.1111/apt.17091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Thakkar KP, Fowler M, Keene S, Iuga A, Dellon ES. Long-term efficacy of proton pump inhibitors as a treatment modality for eosinophilic esophagitis. Dig Liver Dis 2022:S1590-8658(22)00209-2. [PMID: 35410852 DOI: 10.1016/j.dld.2022.03.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Franciosi JP, Mougey EB, Dellon ES, Gutierrez-junquera C, Fernandez-fernandez S, Venkatesh RD, Gupta SK. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions. JAA 2022;Volume 15:281-302. [DOI: 10.2147/jaa.s274524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tamarit-sebastian S, Ferrer-soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ma C, Jairath V, Feagan BG, Guizzetti L, Zou G, McFarlane SC, Shackelton LM, Collins MH, Hirano I, de Rooij WE, Schaeffer DF, Pai RK, Bredenoord AJ, Dellon ES. Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. Am J Gastroenterol 2021. [PMID: 34797816 DOI: 10.14309/ajg.0000000000001571] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Ketchem CJ, Thakkar KP, Xue A, Reddy S, Abramson L, Greenberg SB, Abichandani S, Miller TL, Chang NC, Eluri S, Reed CC, Dellon ES. Older patients with eosinophilic esophagitis have high treatment response to topical steroids. Dig Liver Dis 2021:S1590-8658(21)00809-4. [PMID: 34789398 DOI: 10.1016/j.dld.2021.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chang NC, Thakkar KP, Ketchem CJ, Eluri S, Reed CC, Dellon ES. A Gap in Care Leads to Progression of Fibrosis in Eosinophilic Esophagitis Patients. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01141-1. [PMID: 34718172 DOI: 10.1016/j.cgh.2021.10.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
11 Kanikowska A, Hryhorowicz S, Rychter AM, Kucharski MA, Zawada A, Iwanik K, Eder P, Słomski R, Dobrowolska A, Krela-Kaźmierczak I. Immunogenetic, Molecular and Microbiotic Determinants of Eosinophilic Esophagitis and Clinical Practice-A New Perspective of an Old Disease. Int J Mol Sci 2021;22:10830. [PMID: 34639170 DOI: 10.3390/ijms221910830] [Reference Citation Analysis]
12 Schreiner P, Biedermann L, Greuter T, Wright BL, Straumann A. How to approach adult patients with asymptomatic esophageal eosinophilia. Dis Esophagus 2021;34:doaa105. [PMID: 33016307 DOI: 10.1093/dote/doaa105] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
13 Ketchem CJ, Reed CC, Stefanadis Z, Dellon ES. Treatment with compounded fluticasone suspension improves the clinical, endoscopic, and histologic features of eosinophilic esophagitis. Dis Esophagus 2021;34:doaa120. [PMID: 33306783 DOI: 10.1093/dote/doaa120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Dellon ES, Woosley JT, McGee SJ, Moist SE, Shaheen NJ. Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double dummy clinical trial. Dis Esophagus 2020;33:doaa003. [PMID: 32193541 DOI: 10.1093/dote/doaa003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ma C, Schoepfer AM, Dellon ES, Bredenoord AJ, Chehade M, Collins MH, Feagan BG, Furuta GT, Gupta SK, Hirano I, Jairath V, Katzka DA, Pai RK, Rothenberg ME, Straumann A, Aceves SS, Alexander JA, Arva NC, Atkins D, Biedermann L, Blanchard C, Cianferoni A, Ciriza de Los Rios C, Clayton F, Davis CM, de Bortoli N, Dias JA, Falk GW, Genta RM, Ghaffari G, Gonsalves N, Greuter T, Hopp R, Hsu Blatman KS, Jensen ET, Johnston D, Kagalwalla AF, Larsson HM, Leung J, Louis H, Masterson JC, Menard-Katcher C, Menard-Katcher PA, Moawad FJ, Muir AB, Mukkada VA, Penagini R, Pesek RD, Peterson K, Putnam PE, Ravelli A, Savarino EV, Schlag C, Schreiner P, Simon D, Smyrk TC, Spergel JM, Taft TH, Terreehorst I, Vanuytsel T, Venter C, Vieira MC, Vieth M, Vlieg-Boerstra B, von Arnim U, Walker MM, Wechsler JB, Woodland P, Woosley JT, Yang GY, Zevit N, Safroneeva E; COREOS Collaborators:. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol 2021:S0091-6749(21)01059-9. [PMID: 34242635 DOI: 10.1016/j.jaci.2021.07.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
16 Philpott H, Lee SZ, Arrington A, McGee SJ, Dellon ES. Impact of food challenge on local oesophageal immunophenotype in eosinophilic oesophagitis. Clin Exp Allergy 2020;50:463-70. [PMID: 32012383 DOI: 10.1111/cea.13578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Greenberg S, Chang NC, Corder SR, Reed CC, Eluri S, Dellon ES. Dilation-predominant approach versus routine care in patients with difficult-to-treat eosinophilic esophagitis: a retrospective comparison. Endoscopy 2021. [PMID: 33910259 DOI: 10.1055/a-1493-5627] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lucendo AJ, López-Sánchez P. Targeted Therapies for Eosinophilic Gastrointestinal Disorders. BioDrugs 2020;34:477-93. [PMID: 32472465 DOI: 10.1007/s40259-020-00427-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
19 Kim SJ, Park MI, Kim GH, Lee MW, Jung K, Lee J, Seol SY, Jee SR, Lee HS, Jang JS, Cha JH; Gyeongnam Society of Neurogastroenterology and Motility. Practice Patterns for Eosinophilic Esophagitis Patients in Busan and Gyeongnam: A Korean Multicenter Database Study. J Neurogastroenterol Motil 2021;27:71-7. [PMID: 32699187 DOI: 10.5056/jnm20069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chang N, Raja S, Betancourt R, Randall C, Keene S, Lilly A, Fowler M, Woosley JT, Shaheen NJ, Dellon ES. Generic Measures of Quality of Life Are Not Correlated with Disease Activity in Eosinophilic Esophagitis. Dig Dis Sci 2021. [PMID: 33492534 DOI: 10.1007/s10620-020-06719-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Doyle AD, Masuda MY, Kita H, Wright BL. Eosinophils in Eosinophilic Esophagitis: The Road to Fibrostenosis is Paved With Good Intentions. Front Immunol 2020;11:603295. [PMID: 33335531 DOI: 10.3389/fimmu.2020.603295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
22 Jensen ET, Langefeld CD, Zimmerman KD, Howard TD, Dellon ES. Epigenetic methylation in Eosinophilic Esophagitis: Molecular ageing and novel biomarkers for treatment response. Clin Exp Allergy 2020;50:1372-80. [PMID: 32986922 DOI: 10.1111/cea.13748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Rank MA, Sharaf RN, Furuta GT, Aceves SS, Greenhawt M, Spergel JM, Falck-Ytter YT, Dellon ES; AGA Institute. Electronic address: clinicalpractice@gastro.org., Joint Task Force on Allergy-Immunology Practice Parameters collaborators. Electronic address: drdanawallace@gmail.com., AGA Institute., Joint Task Force on Allergy-Immunology Practice Parameters collaborators. Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters. Gastroenterology 2020;158:1789-1810.e15. [PMID: 32359563 DOI: 10.1053/j.gastro.2020.02.039] [Cited by in Crossref: 11] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
24 Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR, Wang K, Greenhawt M, Falck-Ytter YT; AGA Institute Clinical Guidelines Committee., Joint Task Force on Allergy-Immunology Practice Parameters. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology 2020;158:1776-86. [PMID: 32359562 DOI: 10.1053/j.gastro.2020.02.038] [Cited by in Crossref: 44] [Cited by in F6Publishing: 74] [Article Influence: 22.0] [Reference Citation Analysis]
25 Nennstiel S, Schlag C. Treatment of eosinophlic esophagitis with swallowed topical corticosteroids. World J Gastroenterol 2020; 26(36): 5395-5407 [PMID: 33024392 DOI: 10.3748/wjg.v26.i36.5395] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Dellon ES, Guo R, McGee SJ, Hamilton DK, Nicolai E, Covington J, Moist SE, Arrington A, Wright BL, Burks AW, Vickery BP, Kulis M. A Novel Allergen-Specific Immune Signature-Directed Approach to Dietary Elimination in Eosinophilic Esophagitis. Clin Transl Gastroenterol 2019;10:e00099. [PMID: 31789931 DOI: 10.14309/ctg.0000000000000099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
27 Greuter T, Godat A, Ringel A, Almonte HS, Schupack D, Mendoza G, McCright-Gill T, Dellon ES, Hirano I, Alexander J, Chehade M, Safroneeva E, Bussmann C, Biedermann L, Schreiner P, Schoepfer AM, Straumann A, Katzka DA. Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31136-8. [PMID: 32798703 DOI: 10.1016/j.cgh.2020.08.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Fernandez-Becker NQ, Raja S, Scarpignato C, Lynch KL, Ahuja NK, Horsley-Silva JL. Eosinophilic esophagitis: updates on key unanswered questions. Ann N Y Acad Sci 2020;1481:30-42. [PMID: 32762154 DOI: 10.1111/nyas.14421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Cotton CC, Betancourt R, Randall C, Perjar I, Bookhout C, Woosley JT, Shaheen NJ, Dellon ES. A Model Using Clinical and Endoscopic Characteristics Identifies Patients at Risk for Eosinophilic Esophagitis According to Updated Diagnostic Guidelines. Clin Gastroenterol Hepatol 2021;19:1824-1834.e2. [PMID: 32634625 DOI: 10.1016/j.cgh.2020.06.068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Reddy A, Ashat D, Murali AR. Recent insights on the use of topical steroids in eosinophilic esophagitis. Expert Rev Gastroenterol Hepatol 2020;14:953-63. [PMID: 32567417 DOI: 10.1080/17474124.2020.1785869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
31 Rank MA, Sharaf RN, Furuta GT, Aceves SS, Greenhawt M, Spergel JM, Falck-Ytter YT, Dellon ES; AGA Institute. Electronic address: clinicalpractice@gastro.org., Joint Task Force on Allergy-Immunology Practice Parameters collaborators. Electronic address: drdanawallace@gmail.com., AGA Institute., Joint Task Force on Allergy-Immunology Practice Parameters collaborators. Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters. Ann Allergy Asthma Immunol 2020;124:424-440.e17. [PMID: 32336463 DOI: 10.1016/j.anai.2020.03.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
32 Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR, Wang K, Greenhawt M, Falck-Ytter YT; AGA Institute Clinical Guidelines Committee., Joint Task Force on Allergy-Immunology Practice Parameters. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Ann Allergy Asthma Immunol 2020;124:416-23. [PMID: 32336462 DOI: 10.1016/j.anai.2020.03.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
33 Greuter T, Schoepfer AM, Straumann A. Reply. Clin Gastroenterol Hepatol. 2019;17:2385-2386. [PMID: 31543240 DOI: 10.1016/j.cgh.2019.04.054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Bolton SM, Kagalwalla AF, Arva NC, Wang MY, Amsden K, Melin-Aldana H, Dellon ES, Bryce PJ, Wershil BK, Wechsler JB. Mast Cell Infiltration Is Associated With Persistent Symptoms and Endoscopic Abnormalities Despite Resolution of Eosinophilia in Pediatric Eosinophilic Esophagitis. Am J Gastroenterol 2020;115:224-33. [PMID: 31913192 DOI: 10.14309/ajg.0000000000000474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
35 Eluri S, Perjar I, Betancourt R, Randall C, Raja S, Woosley JT, Shaheen NJ, Dellon ES. Heartburn and dyspepsia symptom severity improves after treatment and correlates with histology in adults with eosinophilic esophagitis. Dis Esophagus 2019;32:doz028. [PMID: 31329864 DOI: 10.1093/dote/doz028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Hiremath G, Correa H, Acra S, Dellon ES. Correlation of endoscopic signs and mucosal alterations in children with eosinophilic esophagitis. Gastrointestinal Endoscopy 2020;91:785-794.e1. [DOI: 10.1016/j.gie.2019.11.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
37 Safroneeva E, Schoepfer AM. Symptom-based patient-reported outcomes in adults with eosinophilic esophagitis: value for treatment monitoring and randomized controlled trial design. Curr Opin Allergy Clin Immunol 2019;19:169-74. [PMID: 30649010 DOI: 10.1097/ACI.0000000000000514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. Gastroenterology 2020;158:840-51. [PMID: 31836530 DOI: 10.1053/j.gastro.2019.09.052] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
39 Godwin B, Wilkins B, Muir AB. EoE disease monitoring: Where we are and where we are going. Ann Allergy Asthma Immunol 2020;124:240-7. [PMID: 31830586 DOI: 10.1016/j.anai.2019.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
40 Dellon ES. No Maintenance, No Gain in Long-term Treatment of Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2019;17:397-9. [PMID: 30678839 DOI: 10.1016/j.cgh.2018.07.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
41 Kim GH, Park YS, Jung KW, Kim M, Na HK, Ahn JY, Lee JH, Kim DH, Choi KD, Song HJ, Lee GH, Dellon ES, Jung HY. An Increasing Trend of Eosinophilic Esophagitis in Korea and the Clinical Implication of the Biomarkers to Determine Disease Activity and Treatment Response in Eosinophilic Esophagitis. J Neurogastroenterol Motil 2019;25:525-33. [PMID: 31587544 DOI: 10.5056/jnm19066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
42 Greuter T, Alexander JA, Straumann A, Katzka DA. Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use. Clin Transl Gastroenterol 2018;9:e212. [PMID: 30802222 DOI: 10.1038/s41424-018-0074-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
43 Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Galanko JA, Baron JA, Shaheen NJ. Rapid Recurrence of Eosinophilic Esophagitis Activity After Successful Treatment in the Observation Phase of a Randomized, Double-Blind, Double-Dummy Trial. Clin Gastroenterol Hepatol. 2020;18:1483-1492.e2. [PMID: 31499249 DOI: 10.1016/j.cgh.2019.08.050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
44 Frazzoni M, Penagini R, Frazzoni L, de Bortoli N, Mauro A, Tolone S, Bertani H, Marsico M, Marocchi M, Marchi S, Conigliaro R, Savarino E. Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring. Am J Gastroenterol 2019;114:1606-13. [DOI: 10.14309/ajg.0000000000000379] [Cited by in Crossref: 14] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
45 Conner JR, Kirsch R. Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE-HSS)-an important first step. Aliment Pharmacol Ther 2018;47:1713-4. [PMID: 29878506 DOI: 10.1111/apt.14633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Peterson KA, Gleich GJ, Limaye NS, Crispin H, Robson J, Fang J, Saffari H, Clayton F, Leiferman KM. Eosinophil granule major basic protein 1 deposition in eosinophilic esophagitis correlates with symptoms independent of eosinophil counts. Diseases of the Esophagus 2019. [DOI: 10.1093/dote/doz055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
47 Ananthakrishnan AN. Issue Highlights. Clinical Gastroenterology and Hepatology 2019;17:1011-4. [DOI: 10.1016/j.cgh.2019.03.002] [Reference Citation Analysis]
48 Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Tylicki AE, Shoyoye SO, Martin CF, Galanko JA, Baron JA, Shaheen NJ. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. Gastroenterology. 2019;157:65-73.e5. [PMID: 30872104 DOI: 10.1053/j.gastro.2019.03.014] [Cited by in Crossref: 37] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
49 Dellon ES, Gupta SK. A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2019;17:2149-2160. [PMID: 30710696 DOI: 10.1016/j.cgh.2019.01.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
50 Reed CC, Iglesia EGA, Commins SP, Dellon ES. Seasonal exacerbation of eosinophilic esophagitis histologic activity in adults and children implicates role of aeroallergens. Ann Allergy Asthma Immunol 2019;122:296-301. [PMID: 30578860 DOI: 10.1016/j.anai.2018.12.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
51 Ma C, van Rhijn BD, Jairath V, Nguyen TM, Parker CE, Aceves SS, Furuta GT, Gupta SK, Katzka DA, Safroneeva E, Schoepfer AM, Straumann A, Spergel JM, Pai RK, Feagan BG, Hirano I, Dellon ES, Bredenoord AJ. Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. Clinical Gastroenterology and Hepatology 2018;16:1714-1729.e3. [DOI: 10.1016/j.cgh.2018.06.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
52 Biedermann L, Straumann A. Medical and dietary treatments in eosinophilic esophagitis. Curr Opin Pharmacol 2018;43:139-44. [PMID: 30336406 DOI: 10.1016/j.coph.2018.08.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
53 Eluri S, Selitsky SR, Perjar I, Hollyfield J, Betancourt R, Randall C, Rusin S, Woosley JT, Shaheen NJ, Dellon ES. Clinical and Molecular Factors Associated With Histologic Response to Topical Steroid Treatment in Patients With Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2019;17:1081-1088.e2. [PMID: 30213583 DOI: 10.1016/j.cgh.2018.09.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
54 Steinbach EC, Hernandez M, Dellon ES. Eosinophilic Esophagitis and the Eosinophilic Gastrointestinal Diseases: Approach to Diagnosis and Management. J Allergy Clin Immunol Pract 2018;6:1483-95. [PMID: 30201096 DOI: 10.1016/j.jaip.2018.06.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
55 Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Román E. The Role of Proton Pump Inhibitors in the Management of Pediatric Eosinophilic Esophagitis. Front Pediatr 2018;6:119. [PMID: 29868522 DOI: 10.3389/fped.2018.00119] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
56 Zhan T, Ali A, Choi JG, Lee M, Leung J, Dellon ES, Garber JJ, Hur C. Model to Determine the Optimal Dietary Elimination Strategy for Treatment of Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2018;16:1730-1737.e2. [PMID: 29730438 DOI: 10.1016/j.cgh.2018.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
57 Munoz-Persy M, Lucendo AJ. Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach. Eur J Pediatr 2018;177:649-63. [PMID: 29549437 DOI: 10.1007/s00431-018-3129-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
58 Kanwal F. Issue Highlights. Clinical Gastroenterology and Hepatology 2018;16:155-6. [DOI: 10.1016/j.cgh.2017.12.021] [Reference Citation Analysis]